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http://dx.doi.org/10.1016/j.pedneo.2Rotavirus infection has been the leading cause of gastroenteritis among children in Taiwan.
Studies have shown that 40% of hospitalization for acute gastroenteritis can be prevented
through the use of vaccines, including a live, attenuated monovalent rotavirus vaccine and
a pentavalent, humanebovine reassortant rotavirus vaccine. In 2009, the World Health Orga-
nization suggested that rotavirus vaccine should be included in all national immunization pro-
grams. This review summarizes issues and recommendations discussed during an expert
meeting in Taiwan. The recommendations included: (1) rotavirus vaccine should be offered
to all healthy infants (including those without contraindications, such as immunodeficiency)
at an appropriate age; (2) either monovalent or pentavalent vaccine can be administeredChildren’s Hospital, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University,
an, Taiwan.
org.tw (T.-Y. Lin).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
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356 P.-I. Lee et alconcurrently with routine injected vaccines; (3) the administration of rotavirus vaccine must
be administered at least 2 weeks prior to oral polio vaccination; (4) the first vaccine dose
for infants should be administered between age 6 weeks and age 14 weeks 6 days and the
course should be completed by age 8 months 0 day; (5) pentavalent vaccines can be adminis-
tered at 2 months, 4 months, and 6 months while monovalent vaccines can be taken at 2
months and 4 months; (6) a combined use of monovalent and pentavalent vaccine is justified
only when the previous dose is unavailable or unknown; and (7) rotavirus vaccines may be given
to premature infants, human immunodeficiency virus infected infants and infants who have
received or are going to receive blood products.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction associated diarrhea in young children was decreased toRotavirus infection is a global disease. Viability of the virus
may be maintained for 6e60 days in the environment.1
People contract the virus quite frequently, and the symp-
toms are usually mild or asymptomatic in infected adults.
By contrast, severe diarrhea and dehydration are not
infrequent in infants, children aged <5 years, the elderly
and immunocompromised patients, which is the reason why
rotavirus infection is also known as infantile cholera. In
addition to the nonstop diarrhea, infants with rotavirus-
related diarrhea often contribute psychological stress to
their parents, including anxiety, fear, frustration and other
emotional distress.
2. Epidemiology
In both developed and developing countries, rotavirus
infection accounts for 30e50% of gastroenteritis in hospi-
talized children and 10e15% of diarrhea in children with
community-acquired gastroenteritis. Rotavirus-related
mortality is an important issue in developing countries. It
is estimated that 600,000 infants and young children die
from rotavirus-related diarrhea each year worldwide. In
low-income countries, one out of every 205 cases with
rotavirus infection will die. Rotavirus-related death is rare
in high-income countries, with an estimated mortality rate
of 1/50,000.2
In Taiwan, rotavirus infections are prevalent from
November to May with a peak between February and March.
The cumulative rotavirus infection rate among young chil-
dren in Taiwan is 22% before age 1 year and increases to 53%
before age 2 years. Rotavirus infection remains the leading
cause of acute viral gastroenteritis in children aged <5
years in Taiwan. In recent years, the incidence of diarrhea
among children aged <5 years has reduced greatly due to
the improvements in hygiene.3 However, rotavirus remains
an important etiology of childhood diarrhea. A study be-
tween December 2004 and June 2006 showed that rotavirus
accounted for 46% of acute gastroenteritis in hospitalized
children and 14% of acute gastroenteritis in pediatric
outpatient clinics.4 After the two rotavirus vaccines
became available in Taiwan from the end of 2006, the
positive rate of rotavirus infection in children with acute
diarrhea seemed to decrease. Currently, surveillance data
from the Centers for Disease Control, Taiwan and three
sentinel hospitals located in the northern, central, and
southern Taiwan revealed that the proportion of rotavirus-around 20%.5 However, it is not clear whether the change
was directly linked to the use of vaccines.
Two oral rotavirus vaccines are currently available,
including a pentavalent vaccine (RotaTeq; Merck and
Company, Whitehouse Station, NJ, USA) and a monovalent
vaccine (Rotarix, GlaxoSmithKline Biologicals, Rixensart,
Belgium). The pentavalent vaccine is a humanebovine
reassortant rotavirus vaccine containing human rotavirus
types G1, G2, G3, G4 and P[8] and is given as a three-dose
series.6 The monovalent vaccine is a live attenuated rota-
virus vaccine containing human rotavirus type G1P[8] and is
given as a two-dose series.73. Efficacy of Rotavirus Vaccines
All premarketing clinical trials and postmarketing surveil-
lance in many countries conclude that rotavirus vaccines
are very effective to protect infants and young children
from rotavirus-related disease. Both vaccines are 90e95%
efficacious in preventing severe rotavirus gastroenteritis.
Recently, a follow-up study was conducted on 279 new-
borns at Chang Gung Memorial Hospital in Linkou. Their
vaccination history and health-related parameters were
obtained through telephone contact. Both rotavirus vac-
cines were shown to be able to reduce the occurrence of
gastroenteritis significantly during the first 2 years of life.
However, causative agents of diarrhea were not deter-
mined in this study. Another caseecontrol study recruited
around 1000 children aged <5 years with diarrhea who were
admitted to Changhua Christian Hospital or Chang Gung
Memorial Hospital at Linkou and Kaohsiung from May 2009
to June 2010. The results revealed that both monovalent
and pentavalent vaccines were effective in preventing
about 40% of hospitalizations for acute gastroenteritis by
any cause. The vaccine effectiveness against hospitaliza-
tion for rotavirus-associated acute gastroenteritis was
70e90%, and it was impressively up to 80e95% for in-
dividuals who had completed the vaccination schedule.4. Cost-effectiveness of Rotavirus Vaccines
The World Health Organization recognizes the excellent
protective efficacy of rotavirus vaccines and the impor-
tance of using them to decrease the associated morbidity
and mortality of rotavirus gastroenteritis in young children
in developing countries. However, cost-effectiveness of
Rotavirus vaccine 357rotavirus vaccine varies among different countries with
different epidemiological features.
To investigate the disease burden and related medical
costs of rotavirus infections in Taiwan, a retrospective
study was performed on children with acute gastroenter-
itis at three hospitals in 2001. The results showed that
rotavirus was the most common etiology of acute gastro-
enteritis in children aged <5 years with a detection rate of
32.9% of inpatients and a detection rate of 24% in out-
patients. On average, it cost US$ 10.8 (NTD$ 365) for each
ambulatory visit and US$ 336.0 (NTD$ 11,356.8) for each
hospitalization due to acute gastroenteritis.8 Another
study investigated the economic burden of rotaviral,
bacterial, and all-cause diarrhea in children aged <5 years
from 2001 to 2003 in Taiwan. Mean direct costs associated
with rotavirus infection, including outpatient cost and
hospitalization fee, were estimated to be US$676
(NTD$23,660) per child, and mean indirect costs, such as
costs of caregivers’ time lost, were estimated to be
US$185 (NTD$6,475) per child.9 On average, each family
spent US$294 (NTD$10,290) for one episode of rotavirus
infection in children with admission, which is about 40% of
the monthly salary of an unskilled or service worker in
Taiwan.9
According to international cost-effectiveness studies,
the price of the vaccine is one of the key factors influencing
the result of cost-effectiveness of rotavirus vaccination.
Rotavirus vaccine may be cost-effective if it costs no more
than US$40e62.5 per dose in the USA, and if it costs no
more than US$21e64.5 (UK£13e40) per course in the UK.10
To be cost-effective, the cost per course must be reduced
to be no more than US$1e20 in low-income countries such
as Vietnam.10 In developing countries, the types of rota-
virus are more diverse, malnutrition is more common, and
the vaccination rate is lower. As a consequence, the pro-
tective efficacy of vaccine may be lower in these countries.
Studies show that the cost-effectiveness of rotavirus
vaccination is highly sensitive to vaccine prices, rotavirus-
associated mortality, and discount rates.11 Among these,
the discount rate is used to compare the effects of vacci-
nation in different years or different programs. A cost-
effectiveness analysis usually converts the expected future
streams of cost and benefits into present value amount using
a discount rate. Rotavirus-associated mortality and discount
rates are fixed and short-term changes are limited. There-
fore, it is the vaccine price that mainly determines the cost-
effectiveness of vaccination. A study assessing the cost-
effectiveness of universal vaccination with pentavalent
rotavirus vaccine in Taiwan concluded that universal vacci-
nation would result in substantial reduction in morbidity of
rotavirus gastroenteritis by 60% and in hospitalization rate
by 92%.12 The vaccine may be cost-saving at a price of US$20
per dose in Taiwan. It is noteworthy that such cost-
effectiveness analyses have not taken into account the
psychological burden associated with rotavirus infections in
sick children and their caregivers.5. Recommendations on Rotavirus Vaccination
The rotavirus vaccine has not been included in the national
immunization program in Taiwan. An expert meeting wasorganized and recommendations for rotavirus vaccine in
various countries were reviewed. The following are the
recommendations of rotavirus vaccination made by the
expert meeting.
Recommendation 1
Rotavirus vaccination should be offered to all infants of
appropriate age.
The expert meeting recommends that rotavirus vacci-
nation should be offered to all healthy infants of appro-
priate age. Healthy infant refers to all infants without
contraindication to rotavirus vaccine, including allergy to
the component of rotavirus vaccine and infants with se-
vere immunodeficiency. In 2009, the World Health Orga-
nization recommended that rotavirus vaccine for infants
should be included in all national immunization programs.
In countries where diarrheal deaths account for 10% of
mortality among children aged <5 years, the introduction
of the vaccine is strongly recommended.13 The USA was
the first country to include rotavirus vaccine in the na-
tional vaccination program. The European Society for
Paediatric Infectious Diseases (ESPID) and European Soci-
ety for Paediatric Gastroenterology, Hepatology and
Nutrition (ESPGHAN) also recommended that rotavirus
vaccination should be offered to all healthy infants.14 In
countries where rotavirus vaccine has not been used
routinely, there were several recommendations or guide-
lines proposed by academic societies.15 In 2007, the
AsiaePacific Rotavirus MetaForum also suggested that all
infants should receive rotavirus vaccination, and rotavirus
vaccine should be included in national immunization
programs.16
Recommendation 2
Rotavirus vaccine, either monovalent or pentavalent, can
be administered concomitantly with routine injected
vaccines.
Existing studies revealed that oral rotavirus vaccine can
be coadministered with routine injected vaccines for chil-
dren, including diphtheria/tetanus/acellular pertussis/
Haemophilus influenzae type b/injected polio vaccine
(DTaP-Hib-IPV), pneumococcal conjugate vaccine, and
hepatitis B vaccine. This is true for both pentavalent and
monovalent rotavirus vaccines.17
Recommendation 3
A minimum interval of 2 weeks is recommended for the
administration of rotavirus vaccination and oral polio
vaccination.
Coadministration of the oral polio and rotavirus vaccines
may be accompanied by an interference on immunoge-
nicity, especially with regards to that of rotavirus vac-
cine.18,19 Taiwan included DTaP-Hib-IPV to the national
immunization program from 2010. Infants and young chil-
dren will no longer receive oral polio vaccine. In special
circumstances, such as immigrants, an interval of at least 2
weeks is recommended between the rotavirus and oral
358 P.-I. Lee et alpolio vaccines. It is preferred that rotavirus vaccination
precedes oral polio vaccination.
Recommendation 4
Thefirst dose of oral rotavirus vaccine should be administered
between age of 6 weeks, and age 14 weeks 6 days. The last
dose should be completed by age 8 months 0 day. The mini-
mum interval between doses is 4 weeks. Pentavalent vaccine
can be administered at the ages of 2 months, 4 months, and
6 months and monovalent vaccine can be administered at
the ages of 2 months and 4 months. If the first dose is
administered beyond the recommended age, subsequent
doses can be continued to complete the schedule.
The package inserts of the vaccines, the Advisory Com-
mittee on Immunization Practices (ACIP) of the USA, and
ESPID/ESPGHAN have different recommendations on the
age for the first dose of rotavirus vaccine and the age limit
for completing the vaccination schedule (Table 1).14,17,20,21
Combining the two different recommended schedules
for the two vaccines, ACIP recommends the same age limits
for the first dose and the same maximum age for the last
dose for the two rotavirus vaccines.17 The expert meeting
adopts this recommendation. There are insufficient data
available to ensure the safety of delaying the first dose and
the last dose of rotavirus vaccine beyond the above-
mentioned time frame.
The first dose of DTaP-Hib-IPV is now given routinely to
infants at 2 months. The first dose of rotavirus vaccine may
be administered concomitantly with the first dose of DTaP-
Hib-IPV at 2 months.
Recommendation 5
Combined use of monovalent and pentavalent rotavirus
vaccines is not recommended. However, vaccination should
not be deferred because the specific vaccine used for a
previous dose(s) is not available or is unknown. In these
circumstances, the vaccination series may be continued or
completed by using either available rotavirus vaccine.
Since there are no efficacy and safety data on the
combined use of the two rotavirus vaccines, it is not rec-
ommended that they be used in combination. On the other
hand, there is no theoretical safety concern when the two
vaccines are used in sequence. In terms of efficacy, using
two vaccines to complete a series may be better than usingTable 1 Recommendations on schedule for administration of ro
Package inserts
Age for the first dose RotaTeq: 6e12 wk
Rotarix: 6e16 wk
Maximum age for the last dose RotaTeq: 32 wk
Rotarix: 24 wk
Minimal interval RotaTeq: 4e10 wk
Rotarix: at least 4 wk
ACIP Z Advisory Committee on Immunization Practices (USA); E
ESPGHAN Z European Society for Paediatric Gastroenterology, Hepatonly one vaccine for an incomplete series. It is therefore
reasonable to recommend that the two vaccines may be
used in combination in special circumstances, and a total of
three doses of rotavirus vaccine should be administered. All
doses should be given by age 8 months and 0 days.
Recommendation 6
Premature infants may receive rotavirus vaccination ac-
cording to their chronological age. Rotavirus vaccine is not
recommended for infants with severe immunodeficiency.
However, infants with human immunodeficiency virus in-
fections may receive the vaccine. Rotavirus vaccines may
be given to infants who have received or are going to
receive blood products.
Results from the pentavalent rotavirus vaccines trial in
premature infants revealed similar safety and efficacy as
those in term infants. Monovalent rotavirus vaccines have
been evaluated in a relatively small number of premature
infants. The results showed that the vaccine was immuno-
genic.17 These studies also suggested that premature in-
fants may receive rotavirus vaccines according to their
chronological age, rather than adjusted age.
Use of live attenuated vaccine may be associated with
serious adverse reactions in immunocompromised hosts,
and this is one important safety concern for oral rotavirus
vaccines.22 Rotavirus vaccine in infants with severe
combined immunodeficiency had been shown to be asso-
ciated with gastroenteritis and prolonged viral shed-
ding.23 The vaccines are not recommended in such
patients with severe immunodeficiency. Clinical trials of
rotavirus vaccine in Africa did not exclude infants with
human immunodeficiency virus (HIV) infection. HIV-
infected infants did not experience more adverse re-
actions.24 In addition, there is usually no serious immu-
nosuppression in HIV-infected infants at the age at which
rotavirus vaccines are first given, and there is no safety
concern of the use of other live vaccines in such infants.
Rotavirus vaccine may be recommended for use in HIV-
infected infants.
The live attenuated rotavirus vaccine may replicate in
the intestine where a protective immune response is
induced. Systemically administered, blood products are not
expected to interfere with the intestinal immune response.
Therefore, the rotavirus vaccines can be administered to
infants who have received or are going to receive any blood
products, including antibody-containing products.tavirus vaccines.
ACIP ESPID/ESPGHAN
Maximum age: 14 wk 6 d 6e12 wk
8 mo 0 d 6 mo
At least 4 wk (Not mentioned)
SPID Z European Society for Paediatric Infectious Diseases;
ology and Nutrition.
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